Povetacicept Cuts Proteinuria in IgA Nephropathy in Phase 3 Interim Analysis
Start here
An interim analysis of the phase 3 RAINIER AIS-D08 trial, published in the New England Journal of Medicine, found that povetacicept reduced the 24-hour urinary protein-to-creatinine ratio at week 36 by 49.8 percentage points more than placebo in patients with IgA nephropathy (95% CI -58.6 to -39.2, P<0.001). The result positions povetacicept as a strong candidate for treating the protein-driven kidney damage characteristic of the disease. What remains open is the full trial outcome, including longer-term efficacy and safety data beyond this interim proteinuria endpoint.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- N Engl J MedPickInterim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy.
An interim analysis of the phase 3 RAINIER AIS-D08 trial showed povetacicept reduced the 24-hour urinary protein-to-creatinine ratio at week 36 by 49.8 percentage points more than placebo in patients with IgA nephropathy (95% CI -58.6 to -39.2, P<0.001).
Heat trend for this story
Heat now 7·Peak in the comparable set 10 (Oct 24 01:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.